Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Federico

Showing results (151-160 of 233) with videos related to

Pageof 24
Sort By:
Leukemia & Lymphoma|June 21, 2012
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective studyAngelo M Carella, Carmino A de Souza, Stefano Luminari, et al.
The New England Journal of Medicine|June 23, 2016
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's LymphomaPeter Johnson, Massimo Federico, Amy Kirkwood, et al.
Haematologica|January 18, 2015
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL studyDavide Rossi, Alessio Bruscaggin, Piera La Cava, et al.
Hemasphere|June 25, 2026
Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-upDennis A Eichenauer, Marc André, Peter Borchmann, et al.
Leukemia & Lymphoma|September 8, 2011
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano LinfomiFrancesco Merli, Stefano Luminari, Giuseppe Rossi, et al.
Haematologica|September 16, 2017
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trialsDennis A Eichenauer, Ingrid Becker, Ina Monsef, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor projectMassimo Federico, Monica Bellei, Luigi Marcheselli, et al.
Cancer Epidemiology|July 10, 2012
Regional inequalities in cancer care persist in Italy and can influence survivalMilena Sant, Pamela Minicozzi, Claudia Allemani, et al.
Plos One|September 8, 2011
Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemiaFrancesco Maura, Giovanna Cutrona, Sonia Fabris, et al.
Leukemia & Lymphoma|February 23, 2011
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi studyMichael Mian, Gianluca Gaidano, Annarita Conconi, et al.
Pageof 24

Showing results (151-160 of 233) with videos related to

Sort By:
Pageof 24
Leukemia & Lymphoma|June 21, 2012
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective studyAngelo M Carella, Carmino A de Souza, Stefano Luminari, et al.
The New England Journal of Medicine|June 23, 2016
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's LymphomaPeter Johnson, Massimo Federico, Amy Kirkwood, et al.
Haematologica|January 18, 2015
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL studyDavide Rossi, Alessio Bruscaggin, Piera La Cava, et al.
Hemasphere|June 25, 2026
Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-upDennis A Eichenauer, Marc André, Peter Borchmann, et al.
Leukemia & Lymphoma|September 8, 2011
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano LinfomiFrancesco Merli, Stefano Luminari, Giuseppe Rossi, et al.
Haematologica|September 16, 2017
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trialsDennis A Eichenauer, Ingrid Becker, Ina Monsef, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor projectMassimo Federico, Monica Bellei, Luigi Marcheselli, et al.
Cancer Epidemiology|July 10, 2012
Regional inequalities in cancer care persist in Italy and can influence survivalMilena Sant, Pamela Minicozzi, Claudia Allemani, et al.
Plos One|September 8, 2011
Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemiaFrancesco Maura, Giovanna Cutrona, Sonia Fabris, et al.
Leukemia & Lymphoma|February 23, 2011
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi studyMichael Mian, Gianluca Gaidano, Annarita Conconi, et al.
Pageof 24